Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

1.4%

1 terminated/withdrawn out of 74 trials

Success Rate

95.8%

+9.2% vs industry average

Late-Stage Pipeline

41%

30 trials in Phase 3/4

Results Transparency

2 of 23 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

28(45.9%)

Phase 2

14(23.0%)

N/A

13(21.3%)

Phase 1

4(6.6%)

Phase 3

2(3.3%)

61Total

Phase 4(28)

Phase 2(14)

N/A(13)

Phase 1(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (74)

Showing 20 of 74 trials

NCT05328778Phase 4Completed

Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

Role: lead

NCT07462949Not ApplicableCompleted

EC50 of Ciprofol Combined With Remifentanil for Inhibiting Tracheal Responses in Patients Undergoing Gynecological Surgery: a Two-phase Up-and-down Sequential Allocation Study

Role: lead

NCT07265544Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Role: collaborator

NCT07303348Not ApplicableActive Not Recruiting

Multicenter Clinical Randomized Controlled Trial of Unilateral Biportal Endoscopic Spinal Surgery for Degenerative Grade 1 Spondylolisthesis Complicated With Lumbar Spinal Stenosis

Role: collaborator

NCT07145697Phase 4Recruiting

The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness

Role: lead

NCT06763666Phase 4Not Yet Recruiting

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Role: collaborator

NCT05202899Phase 4Unknown

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Role: lead

NCT05187455Phase 4Unknown

Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation